受者年龄对儿童造血细胞移植中移植物抗宿主病及总生存的影响
该研究纳入2002至2020年间14 099例≤21岁首次接受异基因造血细胞移植的患者,按受者年龄分为0~2岁、3~12岁和13~21岁三组,比较急性与慢性GVHD发生率及其对总生存和移植相关死亡率的影响。结果显示,中/重度慢性GVHD发生率随年龄增长而升高;在非恶性疾病患者中,年长儿童重度急性GVHD风险更高;重度急性GVHD和中/重度慢性GVHD均与较差的总生存独立相关。
要点
- 中/重度慢性GVHD发生率随受者年龄增长而升高。
- 非恶性疾病年长儿童重度急性GVHD风险更高。
- 重度急性GVHD和中/重度慢性GVHD均与较差总生存独立相关。
核心结论
- 中/重度慢性GVHD风险随受者年龄增长而增加。
- 非恶性疾病年长患者重度急性GVHD风险增加。
- 儿童GVHD总体发生率虽低,但重度急性GVHD和中/重度慢性GVHD均与显著更差的总生存相关。
研究设计与样本
- 回顾性分析纳入2002至2020年14 099例≤21岁首次接受异基因造血细胞移植的患者。
- 按受者年龄分为0~2岁(婴幼儿)、3~12岁(学龄期)和13~21岁(青少年/年轻成人)三组。
主要发现
- 第100天2~4级和3~4级急性GVHD在各年龄组间无差异,但非恶性疾病患者中年长患者重度急性GVHD发生率小幅增加。
- 1年内中/重度慢性GVHD发生率随年龄增长而升高,调整患者、供者和移植特征后年龄影响仍相似。
- 重度急性GVHD和中/重度慢性GVHD均与较差的总生存独立相关。
- 在恶性疾病患者中,重度急性GVHD和中/重度慢性GVHD均与移植相关死亡率风险增加相关。
临床怎么用
- 在移植咨询时应考虑GVHD结局,尤其是年长儿童和非恶性疾病患者。
- 需改进儿童GVHD的预防和治疗策略以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in graft-versus-host disease (GVHD) prevention and treatment have resulted in expanded donor options and improvement in treatment-related mortality (TRM). This analysis aimed to compare the incidence of acute and chronic GVHD (aGVHD and cGVHD, respectively) in pediatric patients by recipient age and to evaluate the impact of GVHD on overall survival (OS) and TRM. We included 14 099 patients aged ≤21 years who received their first allogeneic hematopoietic cell transplantation from 2002 to 2020, categorizing recipient age as 0 to 2 years (infants/toddlers), 3 to 12 years (school-aged), and 13 to 21 years (adolescent/young adult). There was no difference in grade 2 to 4 and 3 to 4 aGVHD by day 100 among age groups, except among patients with nonmalignant disease (NMD), among whom there was a small increase in incidence of severe aGVHD in older patients. Incidence of moderate/severe cGVHD by 1 year was higher with age. A similar impact of age was observed after adjusting for patient, donor, and transplant characteristics. Risk of severe aGVHD was higher in older children with NMD. Severe aGVHD and moderate/severe cGVHD were independently associated with inferior OS. In patients with malignant disease, both severe aGVHD and moderate/severe cGVHD were associated with increased risk of TRM. In conclusion, risk of moderate/severe cGVHD increases with recipient age, and risk of severe aGVHD is increased among older patients with nonmalignant conditions. Despite the low overall incidence of aGVHD and cGVHD in children, both are associated with significantly worse survival. These data highlight the need to consider GVHD outcomes at time of consultation and for improved prevention and treatment approaches.
引用
- Nishitani M, Graham RA, Wang T, et al. Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients. Blood Adv. 2026. PMID: 41385339. doi:10.1182/bloodadvances.2025017393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。